Method for shortening period of PDX model for xenograft of human tumor

Abstract

The invention discloses a method for shortening the period of a PDX model for xenograft of a human tumor. During the PDX model building period, spinal cord mesenchymal stem cells and matrix gel Matrigel are used for pretreating tumor tissues or tumor cell lines of a patient, and the treated tumor tissue or tumor cell of the patient is inoculated with an immunodeficient mouse (Balb / c or NOD / SCID) to manufacture a preclinical tumor model. The construction period of the solid tumor PDX model is obviously shortened, and the success rate is improved. The invention especially relates to a preparation method for a cancer mouse model with high wettability and metastasis. The method for shortening the period of the human tumor xenograft PDX model has important value for early clinical evaluation, treatment and prognosis observation of solid tumors.

Description

technical field [0001] The invention relates to the field of medicine, to a method for establishing an animal model, in particular to a method for establishing a mouse model of transplanted tumor from human solid tumor tumor tissue. Background technique [0002] One of the recognized pitfalls in the field of cancer research is the lack of model systems capable of studying carcinogenesis and cancer therapy. In order to evaluate the effect of cancer therapy in preclinical and clinical research, human tumor cell lines or patient-derived tumors are usually transplanted into tumor animal models in immunodeficient mice, that is, a patient-derived xenograft model (patient-derived xenograft model, PDX model). The PDX model retains the primary tumor microenvironment and histopathological and genetic characteristics, which is of great significance for screening anticancer drugs and predicting patient efficacy, toxicity, and absorption. In addition, the PDX model can retain the chara...

AI Technical Summary

Problems solved by technology

[0003] However, the PDX model cycle includes transplantation of human tumor cell lines or patient-derived tumors, proliferation and passage of tumor cells in mice, and the whole process takes about 6-12 months, which cannot meet the clinical needs of individualized chemotherapy regimens after surgery. need

Moreover, the success rate of PDX modeling is currently low, which is mainly limited by multiple factors such as tumor type, tumor malignancy, tumor cell ratio in tissue, tissue isolation time, recipient mice, operation technique, transplantation site, and feeding environment.